Journal
VACCINE
Volume 30, Issue 2, Pages 225-230Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2011.11.010
Keywords
Adjuvant; Vaccine; Immunization; Extra domain-B; Angiogenesis; Cancer
Categories
Funding
- Swedish Research Council
- Swedish Cancer Society
- Swedish Society of Medicine
- Jeanssonis Foundation
- Ake Wiberg Foundation
Ask authors/readers for more resources
We have recently shown that immunization against the extra domain-B (ED-B) of fibronectin, using Freund's adjuvant, reduces tumor growth in mice by 70%. In the present study we compare the immune response generated against ED-B using the non-toxic and biodegradable adjuvant Montanide ISA 720/CpG with the response elicited by Freund's adjuvant. Montanide ISA 720/CpG induced anti-ED-B antibodies with higher avidity and less variable levels between individuals than Freund's. Moreover, the duration of the immune response was longer and the generation of anti-ED-B antibodies in naive mice was faster, when Montanide ISA 720/CpG was used. We conclude that it is possible to replace the mineral oil based adjuvant Freund's with an adjuvant acceptable for human use, which is a prerequisite for transfer of the ED-B vaccine to the clinic. (C) 2011 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available